Research and Markets (http://www.researchandmarkets.com/research/9c66gn/opportunityanalyze)
has announced the addition of the "OpportunityAnalyzer:
Bladder Cancer - Opportunity Analysis and Forecasts to 2017"
report to their offering.
The bladder cancer market in the 6MM to grow modestly from
$239.3m in 2012 to $297.5m in 2017, at a CAGR of 4%.
Despite the Launch of Spectrum Pharmaceuticals' EOquin, Nominal Growth
in US and EU Bladder Cancer Market Is Expected from 2012 to 2017
The authors estimates the bladder cancer market in the US and 5EU
(France, Germany, Italy, Spain, and UK) in 2012 to be valued at $239.3m.
This market is defined as the sales of branded drugs, including Valstar
(US only) and Javlor (Europe only), and major generics regimens across
both markets. Predominantly due to the higher price of drugs, the
majority of sales were generated in the US market, $139.m (58%), with
EU sales estimated to be $99.8m (42%).
By the end of the study period in 2017, The authors forecasts global
sales in the bladder cancer market to increase to $297.5m, at a compound
annual growth rate (CAGR) of 4%. The majority of sales at this point
will still come from the US, with $181.1m (61%), with its market share
increasing marginally from 58% in 2012 to 61% by the end of the forecast
period. Overall, The authors expects an increase in market size
primarily due to a forecast increase in number of incident cases across
the study period in the 6MM and the entrance of EOquin into the market
during the forecast period.
The emergence of Spectrum Pharmaceuticals' EOquin, the only product in
the pipeline to enter the market during the forecast period, will also
have a small incremental effect on the bladder cancer market. Global
sales for EOquin will account for $13.2m in its launch year, 2016, and
$26.1m in 2017, accounting for 8.8% of sales in that year.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.4 Forecast Methodology
4.5 Epidemiological Forecast for Bladder Cancer (2012-2022)
5 Current Treatment Options
5.2 Product Profiles - Major Brands
6 Unmet Needs Assessment and Opportunity Analysis
6.2 Unmet Needs Analysis
6.3 Opportunity Analysis
7 R&D Strategies
7.2 Clinical Trial Design
8 Pipeline Assessment
8.2 Promising Drugs in Clinical Development
8.3 Innovative Early-Stage Approaches
9 Pipeline Valuation Analysis
For more information visit http://www.researchandmarkets.com/research/9c66gn/opportunityanalyze
[ Back To NFVZone's Homepage ]